{"schema_version":"secwatch.filing_event.v1","accession":"0001438133-23-000094","form_type":"8-K","ticker":"TNDM","cik":"0001438133","company_name":"TANDEM DIABETES CARE INC","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.874692+00:00","generated_at":"2026-06-14T12:45:07.549454+00:00","sec_items":["5.07","5.08"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Tandem Diabetes annual meeting results: all director nominees elected, 2023 LTIP approved","bullets":["Stockholders elected 7 directors; Blickenstaff, Cha, Howell, Malagueira, McGroddy-Goetz, Sheridan, Twomey.","2023 Long-Term Incentive Plan approved with 51.8M votes for, 4.1M against.","Named executive officer compensation approved on advisory basis (45.7M for, 10.3M against).","Ernst & Young ratified as auditor for FY2023 (58.1M for, 0.8M against).","Deadline for Rule 14a-8 proposals for 2024 annual meeting: December 14, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001438133-23-000094","json":"https://secwatch.observer/filing/0001438133-23-000094.json","markdown":"https://secwatch.observer/filing/0001438133-23-000094.md","text":"https://secwatch.observer/filing/0001438133-23-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/tndm-20230524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:45:07.549454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e3b8adeffd010d55d400c27fc23cda0694104a3","claim":"TANDEM DIABETES CARE INC shareholders approved To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. at the 2023-05-24 meeting.","evidence_excerpt":"Proposal 4 : To ratify of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 58,058,014 790,996 65,483","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"},{"claim_id":"80002bab5d2681f920fa0f9b999b97fcc44f0920","claim":"TANDEM DIABETES CARE INC shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. at the 2023-05-24 meeting.","evidence_excerpt":"Proposal 3 : To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The proposal received the following votes: For Against Abstain Broker Non-Votes 45,684,932 10,258,454 50,633 2,920,474","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"},{"claim_id":"b9cc78111ea181000a07757fdbe12ff9f5d1a018","claim":"TANDEM DIABETES CARE INC shareholders approved To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. at the 2023-05-24 meeting.","evidence_excerpt":"Proposal 2 : To approve the Company's 2023 Long-Term Incentive Plan, which will replace the 2013 Stock Incentive Plan expiring on November 15, 2023. The proposal received the following votes: For Against Abstain Broker Non-Votes 51,791,463 4,104,680 97,876 2,920,474","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813323000094/0001438133-23-000094-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-24"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}